Latest1 information on COVID-19

18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules

Recruiting

I'm Interested

Trial ID: NCT03824535

Age - 45 Years-N/A Condition - Lung Cancer, Lung - Non-Small Cell (NSCLC), Lung - Small Cell Cancer (SCLC) Gender - All Accepting Healthy Volunteers - No

Purpose

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Official Title

18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules

Stanford Investigator(s)

Carina Mari Aparici
Carina Mari Aparici

Clinical Professor, Radiology - Rad/Nuclear Medicine

Sanjiv Sam Gambhir, MD, PhD

Eligibility


Inclusion Criteria:

   - Pulmonary nodule between the size of 7 to 30 mm. Subjects with multiple nodules may be
   eligible if the dominant nodule is 7 to 30 mm

   - Undergoing standard of care 18F-FDG PET imaging (for indeterminate pulmonary nodule)

   - Current or former cigarette smoker, with >= 20 pack years

   - Documented informed consent

Exclusion Criteria:

   - History or previous diagnosis of lung cancer

   - Cancer diagnosis within the last 5 years

   - Pregnant or nursing

View More
View Less

Intervention(s):

procedure: Computed Tomography

drug: Fludeoxyglucose F-18

drug: Fluorine F 18 L-glutamate Derivative BAY94-9392

procedure: Positron Emission Tomography

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Mahima Goel
 650-723-0371

©2022 Stanford Medicine